SAN FRANCISCO (GenomeWeb News) — Financial cutbacks, under-trained and overworked reviewers, widespread risk aversion, and eroding morale at the US Food and Drug Administration are hurting the agency’s ability to effectively review new drugs, according to a prominent regulatory lawyer.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.